Passage Bio targets FDA to greenlight ALS gene therapy trial
Passage Bio has plans to talk with the US Food and Drug Administration (FDA) to initiate trials of its investigative…
Passage Bio has plans to talk with the US Food and Drug Administration (FDA) to initiate trials of its investigative…
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
One of the largest-head-to-head trials shows that a two-drug regimen of Dovato is as effective as a three-drug regimen of…
Researchers will present data from a ‘first-of-its-kind HIV cure’ stem cell transplant at the upcoming AIDS 2024 Conference. Experts will…
AVEO Oncology has announced a Phase III flop of its advanced metastatic renal cell carcinoma (RCC) combination therapy but has…
Gilead Sciences will announce data from several ongoing trials in human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS)…
Kazia Therapeutics’s stocks have skyrocketed by more than 250% after succeeding in a Phase II/III trial in glioblastoma. The company…
Amylyx Pharmaceuticals is looking to rebuild its pipeline after dropping Relyvrio and acquiring a Phase III ready glucagon-like peptide 1…
CSA Medical has completed enrolment in its SPRAY-CB trial (NCT03893370) for patients with chronic obstructive pulmonary disease (COPD) with chronic…
Spur Therapeutics has announced that its gene therapy candidate for Gaucher disease will soon be moving to a Phase III…